An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination With Adebrelimab and Other Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age 18 to 75 years old (including boundary values)
• Volunteer to participate in this clinical study and sign informed consent;
• ECOG score 0-1;
• Expected survival ≥3 months;
• Patients with locally advanced unresectable or metastatic clear cell renal cell carcinoma confirmed by histology or cytology;
• Tumor tissue samples must be provided for testing
• There is at least one measurable or evaluable lesion that meets the RECIST 1.1 criteria;
• Adequate bone marrow and organ function.
Locations
Other Locations
China
Beijing Cancer Hospital
RECRUITING
Beijing
Contact Information
Primary
Yuting Wang
yuting.wang@hengrui.com
+021-61053363
Backup
Liang Hu
Liang.hu@hengrui.com
18036618148
Time Frame
Start Date: 2026-01-06
Estimated Completion Date: 2030-12
Participants
Target number of participants: 139
Treatments
Experimental: SHR-8068+ Adebrelimab + Bevacizumab
Experimental: SHR-8068+ Adebrelimab +HS-10516
Experimental: SHR-8068+ Adebrelimab + Bevacizumab +HRS-10516
Related Therapeutic Areas
Sponsors
Leads: Suzhou Suncadia Biopharmaceuticals Co., Ltd.